Clinical Trial Update: Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating an MRD-driven adaptive treatment strategy for newly diagnosed multiple myeloma using upfront daratumumab-based therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING